From Groundbreaking Science to the Clinic From Groundbreaking Science to the Clinic From Groundbreaking Science to the Clinic

about receptos

We are a Phase 3 clinical stage biopharmaceutical company focused on discovering, developing and commercializing innovative therapeutics in immune disease. Our lead asset, RPC1063, is being developed as an oral therapy for Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD). The goal of our development strategy for RPC1063 is to demonstrate clinically meaningful differentiation versus other available treatments, including a favorable safety profile.
Meet the team »

news

July 29, 2014
Receptos Announces Appointment of Mary Szela and Richard Heyman, Ph.D. to Board of Directors… MORE »

June 24, 2014
Receptos Announces Closing of Underwritten Public Offering of Common Stock… MORE »

June 18, 2014
Receptos Announces Pricing of Underwritten Public Offering of Common Stock… MORE »

June 17, 2014
Receptos Announces Proposed Underwritten Public Offering of Common Stock… MORE »